Screen 1
Screen 2
Screen 3
Click the “View PDF” button or the Image for a high quality PDF file.
Click BACK in browser to return after viewing PDF.
ePosters can only be viewed by delegates with a ticket or BOPSS members with a paid sibscription
| Title | Lacrimal Gland Biopsy: Diagnostic Yield and Safety Profile from a 14-Year Retrospective Audit in a Tertiary Referral Centre. |
| Number | 322 |
| Author | Caoimhe Normile |
| Principal Unit where research was undertaken | Royal Victoria Eye and Ear Hospital Dublin |
| Purpose | Lacrimal gland enlargement presents a diagnostic challenge, with overlap in presentation between inflammatory and neoplastic disease. Biopsy is often required to exclude malignancy. This study evaluates the diagnostic yield and safety of lacrimal gland biopsy in a tertiary referral centre. |
| Methods | A retrospective review of all lacrimal gland biopsies performed between 2010 and 2024 was conducted. Data collected included patient demographics, clinical features, imaging findings, histopathology, and outcomes including recurrence and post-operative complications. |
| Results | Seventy-nine biopsies were analysed (mean age 49 years; 62% female). Inflammatory pathology was most common (44%); however, neoplastic disease accounted for 32% of cases. Lymphoma was identified in 19% (approximately 1 in 5 patients). Malignant tumours such as adenocarcinoma and metastases were less frequent (5%), pleomorphic adenomas accounted for 7.5% of cases, 12% of biopsies were benign cysts, and 10% of biopsies were normal. Post-operative complications were infrequent, with no vision-threatening events observed. Recurrence was uncommon (<10%). |
| Conclusion | Lacrimal gland biopsy demonstrates a high diagnostic yield with a substantial risk of malignancy and a favourable safety profile. A low threshold for biopsy is supported, as the risk of missed malignancy outweighs procedural risk. |
Additional Authors
| First name | Last name | Hospital / Institution |
|---|---|---|
| Rizwana | Khan |